Active ingredientCeritinibCat. No. P-C115-001CAS 1032900-25-6Family · Pharmaceutical analytical standards
Ceritinib
A second-generation inhibitor of the ALK kinase, for ALK-positive non-small cell lung cancer: approved in the United States in April 2014 for patients whose disease progressed on, or who could not tolerate, crizotinib. This family brings together the active ingredient, labelled standards, nitrosamines and other impurities.
Did you know?Thanks to the breakthrough therapy designation it received in 2013, the FDA approved it four months ahead of the goal date for priority review.
Go to the active ingredient →Active ingredientCeritinibCat. No. P-C115-001CAS 1032900-25-6
Isotopically labelledCeritinib-d7Cat. No. P-C115-002CAS 1632484-77-5
Isotopically labelledN-Nitroso Ceritinib-d7Cat. No. P-C115-003
NitrosamineN-Nitroso CeritinibCat. No. P-C115-004
Impurity2-Chloro-4-fluoro-3-nitrotolueneCat. No. P-C115-005CAS 1805115-44-9
Impurity2-Chloro-4-fluoro-5-nitrotolueneCat. No. P-C115-006CAS 112108-73-3
Impurity2-Chloro-4-fluoro-6-nitrotolueneCat. No. P-C115-007CAS 502496-35-7
ImpurityCeritinib Impurity 1Cat. No. P-C115-008CAS 1032903-62-0No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.